AU2527097A - Substituted 2,3-benzodiazepin-4-ones and the use thereof - Google Patents
Substituted 2,3-benzodiazepin-4-ones and the use thereofInfo
- Publication number
- AU2527097A AU2527097A AU25270/97A AU2527097A AU2527097A AU 2527097 A AU2527097 A AU 2527097A AU 25270/97 A AU25270/97 A AU 25270/97A AU 2527097 A AU2527097 A AU 2527097A AU 2527097 A AU2527097 A AU 2527097A
- Authority
- AU
- Australia
- Prior art keywords
- treating
- ameliorating
- disease
- benzodiazepin
- ones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NRGGDWGRGDCVAF-UHFFFAOYSA-N 2,3-benzodiazepin-4-one Chemical class N1=NC(=O)C=C2C=CC=CC2=C1 NRGGDWGRGDCVAF-UHFFFAOYSA-N 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 2
- 230000002461 excitatory amino acid Effects 0.000 abstract 2
- 239000003257 excitatory amino acid Substances 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000002720 Malnutrition Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001071 malnutrition Effects 0.000 abstract 1
- 235000000824 malnutrition Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1381396P | 1996-03-21 | 1996-03-21 | |
| US60013813 | 1996-03-21 | ||
| PCT/US1997/003462 WO1997034878A1 (en) | 1996-03-21 | 1997-03-21 | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2527097A true AU2527097A (en) | 1997-10-10 |
Family
ID=21761900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU25270/97A Abandoned AU2527097A (en) | 1996-03-21 | 1997-03-21 | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5891871A (enExample) |
| EP (1) | EP1021418B1 (enExample) |
| JP (1) | JP2000506890A (enExample) |
| AT (1) | ATE267177T1 (enExample) |
| AU (1) | AU2527097A (enExample) |
| DE (1) | DE69729227T2 (enExample) |
| DK (1) | DK1021418T3 (enExample) |
| ES (1) | ES2217406T3 (enExample) |
| PT (1) | PT1021418E (enExample) |
| WO (1) | WO1997034878A1 (enExample) |
| ZA (1) | ZA972496B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19604920A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| DE19604919A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US6635632B1 (en) * | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| HU227128B1 (en) * | 1999-07-07 | 2010-07-28 | Egyt Gyogyszervegyeszeti Gyar | New 2,3-benzodiazepine derivatives |
| DE10004572A1 (de) * | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| KR100904011B1 (ko) | 2000-06-12 | 2009-06-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물 및 그의 제조 방법 |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| HU225100B1 (hu) * | 2000-12-21 | 2006-06-28 | Egyt Gyogyszervegyeszeti Gyar | 2,3-Benzodiazepinszármazékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények és alkalmazásuk |
| US6649607B2 (en) * | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
| WO2002098865A2 (fr) * | 2001-06-07 | 2002-12-12 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US6864251B2 (en) * | 2002-12-03 | 2005-03-08 | Vela Pharmaceuticals, Inc. | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines |
| MXPA05005893A (es) * | 2002-12-03 | 2006-02-08 | Vela Pharmaceuticals Inc | Composicion farmaceutica de 1-(3-hidroxi -4-metoxifenil) -4-metil-5 -etil-7, 8-dimetoxi- 5h-2, 3-benzodiazepina y usos de la misma. |
| US6638928B1 (en) | 2002-12-03 | 2003-10-28 | Vela Pharmaceuticals, Inc. | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
| AU2003293405A1 (en) * | 2002-12-03 | 2004-06-23 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
| US7022700B2 (en) * | 2002-12-03 | 2006-04-04 | Vela Pharmaceuticals, Inc. | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines |
| WO2004062616A2 (en) | 2003-01-13 | 2004-07-29 | Cortex Pharmaceuticals, Inc. | Method of treating cognitive decline due to sleep deprivation and stress |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| US20040224943A1 (en) * | 2003-02-19 | 2004-11-11 | Leventer Steven M. | Method of lowering body temperature with (R) - 2,3-benzodiazepines |
| GB0325175D0 (en) * | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| JP2007153755A (ja) * | 2005-12-01 | 2007-06-21 | Gifu Univ | プロリン類縁体 |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| FR2972454B1 (fr) * | 2011-03-08 | 2013-03-01 | Servier Lab | Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2014026997A1 (de) | 2012-08-16 | 2014-02-20 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazepine |
| CA2901352A1 (en) | 2013-02-19 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines |
| EP2958922A1 (de) | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
| US20150376196A1 (en) | 2013-02-22 | 2015-12-31 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| JP2016521755A (ja) | 2013-06-13 | 2016-07-25 | ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー | 代謝障害を治療するための組成物および方法 |
| CA3122705A1 (en) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2085645A1 (en) * | 1970-04-22 | 1971-12-31 | Chimidrog | 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers |
| HU191698B (en) * | 1984-07-27 | 1987-03-30 | Gyogyszerkutato Intezet | Process for producing new 1-aryl-5h-2beta-benzodiazepines |
| HU198494B (en) * | 1986-08-15 | 1989-10-30 | Gyogyszerkutato Intezet | Process for producing new 3,4-dihydro-5h-2,3-benzodiazepine derivative and acid addition salts thereof, as well as pharmaceutical compositions comprising same |
| HU219778B (hu) * | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
| US5550124A (en) * | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| DE19604920A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
-
1997
- 1997-03-20 US US08/821,638 patent/US5891871A/en not_active Expired - Fee Related
- 1997-03-21 JP JP9533496A patent/JP2000506890A/ja not_active Ceased
- 1997-03-21 AU AU25270/97A patent/AU2527097A/en not_active Abandoned
- 1997-03-21 PT PT97916722T patent/PT1021418E/pt unknown
- 1997-03-21 DE DE69729227T patent/DE69729227T2/de not_active Expired - Fee Related
- 1997-03-21 WO PCT/US1997/003462 patent/WO1997034878A1/en not_active Ceased
- 1997-03-21 EP EP97916722A patent/EP1021418B1/en not_active Expired - Lifetime
- 1997-03-21 DK DK97916722T patent/DK1021418T3/da active
- 1997-03-21 ES ES97916722T patent/ES2217406T3/es not_active Expired - Lifetime
- 1997-03-21 AT AT97916722T patent/ATE267177T1/de not_active IP Right Cessation
- 1997-03-24 ZA ZA9702496A patent/ZA972496B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000506890A (ja) | 2000-06-06 |
| DE69729227T2 (de) | 2005-05-04 |
| PT1021418E (pt) | 2004-10-29 |
| US5891871A (en) | 1999-04-06 |
| WO1997034878A1 (en) | 1997-09-25 |
| EP1021418B1 (en) | 2004-05-19 |
| DK1021418T3 (da) | 2004-09-20 |
| DE69729227D1 (de) | 2004-06-24 |
| EP1021418A1 (en) | 2000-07-26 |
| ZA972496B (en) | 1997-10-02 |
| EP1021418A4 (en) | 2001-06-13 |
| ES2217406T3 (es) | 2004-11-01 |
| ATE267177T1 (de) | 2004-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2527097A (en) | Substituted 2,3-benzodiazepin-4-ones and the use thereof | |
| EP0446570A3 (en) | Gabapentin and its derivatives for treating neurodegenerative diseases | |
| PT831799E (pt) | Compostos activos ao nivel de um novo sitio de canais calcicos activados por um receptor uteis no tratamento de disturbios neurologicos | |
| FI113651B (fi) | Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsoliyhdisteiden valmistamiseksi | |
| AU4327101A (en) | Aminoadamantane derivatives as therapeutic agents | |
| DE69334237D1 (de) | Glycinrezeptorantagonisten und ihre verwendung | |
| CA2009578A1 (en) | Excitatory amino acid receptor antagonists | |
| WO1998020864A3 (en) | Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases | |
| MY115977A (en) | Synthetic excitatory amino acids | |
| MY131442A (en) | Excitatory amino acid receptor antagonists | |
| WO1999045011A8 (en) | Glycine transport inhibitors | |
| WO1995018616A3 (en) | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor | |
| WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
| WO1996022990A3 (en) | Aza and aza (n-oxy) analogs of glycine/nmda receptor antagonists | |
| EP0855391A4 (en) | ISOCHINOL DERIVATIVES | |
| AU4713196A (en) | 4-aminotetrahydrobenzisoxazole or -isothiazole compounds | |
| GR3036429T3 (en) | Bicyclic compounds as excitatory amino acid receptor antagonists. | |
| BR0113974A (pt) | Inibidores de aminotransferase dependente de aminoácido de cadeia ramificada e sua utilização no tratamento de doenças neurodegenerativas | |
| DE69526452D1 (de) | Indolditerpen alkaloide | |
| EP0999204A4 (en) | CONNECTIONS TO PROMOTE NEURON DIFFERENTIATION | |
| WO2002055481A8 (en) | Prodrugs of excitatory amino acids | |
| DE60209192D1 (de) | Inhibitore der Verzweigte-Aminosäure-abhängigen Aminotransferase und deren Verwendung in der Behandlung von Neurodegenerativen Erkrankungen | |
| ATE361072T1 (de) | N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors | |
| AU5123200A (en) | 7-oxo-2-azabicyclo(2.2.1)heptanes as selective muscarinic receptor antagonist | |
| WO2002053556A3 (en) | Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |